Xeris Biopharma Holdings (XERS) Peer Comparison

$8.40

$-0.20 (-2.27%)

As on 04-Sep-2026 13:36EDT

Market cap

$1,546 Mln

Revenue (TTM)

$335 Mln

P/E Ratio

--

P/B Ratio

107.7

Div. Yield

0 %

Edit

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	1,546	16,765	16,261	13,492	12,332
Revenue ($ Mln)	335	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-17.17	491.50	755.85	860.62	-325.10
Net Margin (%)	-5.12	17.67	71.69	35.33	-25.32
RoE (%)	--	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	107.68	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	335.41	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	55.87	1,982.07	103.47	85.67	109.42
Gross Profit	238.43	760.62	588.53	2,236.43	902.26
Operating Expenses	242.95	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	36.59	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-17.17	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-17.17	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	-9.73	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	232.07	187.89	384.48	288.55	346.72
Current Liabilities	189.57	1,435.43	464.70	361.93	374.20
Total Liabilities	383.53	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	137.15	1,006.90	895.24	1,243.41	45.47
Current Assets	274.76	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	383.53	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	289.44	120.10	449.89	165.93	347.75
Net Current Assets	85.19	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	28.63	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-0.70	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	11.39	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	0.38	53.56	-30.01	32.82	-31.49
ROE (%)	-6.96	110.09	163.18	42.98	-57.72
ROA (%)	-3.33	15.64	26.53	29.32	-22.97
EBIT Margin (%)	1.17	21.13	5.73	31.04	-18.97
Net Margin (%)	-5.12	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	36.33	24.67	114.85	9.23	149.04
EBIT Growth (%)	176.08	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	46.36	17.50	378.76	42.89	-15.32
EPS Growth (%)	51.90	26.84	353.27	50.42	-0.64
Book Value Growth (%)	54.49	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	2,551.56	36.06	-59.76	15.79	-45.32
Price / Book Value	103.26	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	105.45	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	-19.40	0.00	0.00	0.00	0.65
Short term debt to equity ratio	-7.20	0.00	0.05	0.00	0.00
Current Ratio	1.45	0.73	2.99	3.46	3.20
Quick Ratio	1.02	0.73	2.32	3.38	2.94
Interest Coverage	0.39	--	1.62	--	-19.80

Operating Efficiency Ratios

	Xeris Biopharma Holdings (XERS)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	17.32	15.88	21.25	13.74	14.98
Asset Turnover	0.65	0.89	0.37	0.83	0.91
Receivable days	57.24	50.42	85.52	43.48	35.88
Inventory Days	399.52	--	1,056.70	96.17	354.23
Payable days	18.35	6.26	331.01	147.97	300.79
Cash Conversion Cycle	438.41	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly